KRAS and cancer: However, this can be explored in larger cohorts, as there is also increasing evidence among other types of KRAS-mutant cancer that metformin can influence survival and its efficacy needs further clinical trials in order to find a place in the treatment continuum of mCRC [13,14,15,16].